phase readout
saveNCT04208178: Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
ACTIVE_NOT_RECRUITINGupdated 6m ago
community read0 votes
Sponsor: Novartis Pharmaceuticals. Phase: PHASE3. Conditions: Advanced HER2+Breast Cancer
view source ↗
comments(0)
5-min edit window · permanent after that